10-Q: IR-Med Inc. Reports Q3 2024 Results: Operating Losses Narrow as Company Advances Product Development

IR-Med Inc. reported a reduced net loss for the third quarter of 2024 compared to the same period last year, while progressing with the development and commercialization of its medical devices.

Summary

• IR-Med Inc. reported its financial results for the third quarter of 2024, showing a net loss of $598,000, which is an improvement compared to the $1,179,000 loss in the same quarter of 2023.
• For the nine months ended September 30, 2024, the company's net loss was $1,621,000, also lower than the $3,638,000 loss reported for the same period in 2023.
• The company's research and development expenses decreased significantly, from $1,570,000 in the first nine months of 2023 to $494,000 in the same period of 2024, due to the completion of the PressureSafe device development and a reduction in third-party contractor use.
• Marketing expenses also decreased from $631,000 to $225,000, and general and administrative expenses decreased from $1,448,000 to $898,000 over the same nine-month periods.
• The company received a grant of approximately $387,000 from the Israel Innovation Authority (IIA) to develop a device for the early detection of diabetic foot ulcers.
• As of September 30, 2024, the company had $392,000 in cash and cash equivalents and $531,000 in total liabilities.
• The company has raised $755,000 through private placements of common stock and warrants during the reporting period.
• The company's management has expressed substantial doubt about its ability to continue as a going concern without additional funding.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has made progress in product development and reduced its losses, the going concern warning and need for additional funding are significant concerns. The sentiment is neutral to slightly negative due to the financial risks.

Positives

• The company has successfully reduced its operating losses compared to the previous year.
• The PressureSafe device received FDA listing certification, a key milestone for commercialization.
• The company secured a grant from the IIA to support the development of the DiaSafe device.
• The company has commenced a usability study for the PressureSafe device at a reputable healthcare provider.
• The company has successfully raised additional capital through private placements.

Negatives

• The company's cash resources are limited, with only $392,000 in cash and cash equivalents as of September 30, 2024.
• The company has a significant accumulated deficit of $16,460,000 as of September 30, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company terminated a distribution agreement due to a breach by the distributor.
• The company has reduced compensation for key personnel due to its cash position.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• The company's product development and commercialization efforts are subject to regulatory risks and market acceptance.
• The company faces competition from other medical device companies.
• The company's operations could be affected by the ongoing security situation in Israel.
• The company is involved in a legal proceeding that could result in significant financial liabilities.

Future Outlook

The company plans to launch the PressureSafe device in the first half of 2025 and is continuing the development of the DiaSafe device. The company expects to incur additional costs and will require additional capital to realize its business plans. Management has expressed substantial doubt about the company's ability to continue as a going concern without additional funding.

Management Comments

• Management believes that the general conditions have brought further difficulties in managements efforts to seek additional financing arrangements.
• Management assesses that the current events and the escalation in security in Israel, may have a material effect on its business plans in the short term and may cause delays in the Companys research and development activities and in its marketing efforts.
• Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Industry Context

The company operates in the medical device industry, which is characterized by high research and development costs, regulatory hurdles, and competition. The company's focus on non-invasive diagnostic devices aligns with the trend towards more patient-friendly and cost-effective healthcare solutions. The company's technology platform, which combines infrared spectroscopy and artificial intelligence, is innovative and has the potential to address unmet medical needs.

Comparison to Industry Standards

• IR-Med's focus on early detection of pressure injuries and diabetic foot ulcers aligns with the broader industry trend of preventative healthcare and early intervention.
• Compared to companies like Smith+Nephew and Mölnlycke Health Care, which offer wound care products, IR-Med is focusing on early detection, which could be a differentiating factor.
• The company's use of AI in diagnostics is similar to other companies in the medical technology space, such as Butterfly Network, which uses AI in ultrasound devices.
• The company's financial results, with significant operating losses and reliance on external funding, are typical for early-stage medical device companies.
• The company's cash position and going concern warning are not uncommon for companies in this sector that are pre-revenue and heavily reliant on R&D.

Management Changes

Legal Proceedings

• A lawsuit was filed against the Company, the Subsidiary, and Mr. Aharon Klein in the Tel Aviv District Court of Israel, alleging breach of contract and seeking damages of approximately $2.1 million.
• The company believes that the allegations are baseless and without merit and intends to vigorously defend its rights.

Related Party Transactions

• The company has loans from certain stockholders, with repayment dates extended to December 31, 2025.
• The company made a one-time repayment of NIS 18,750 under the loan agreement to Mr. Klein.
• The company amended consulting agreements with Mr. Aharon Klein and Dr. Yaniv Cohen, reducing their monthly payments in October 2024.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment if the company is unable to secure additional funding.
• Employees may be affected by cost-cutting measures, including reduced compensation.
• Customers and healthcare providers may benefit from the company's innovative medical devices, but the commercial launch is still in the future.
• Suppliers and creditors may be impacted by the company's financial instability.

Next Steps

• The company plans to launch the PressureSafe device in the first half of 2025.
• The company will continue the development of the DiaSafe device.
• The company will seek additional financing to continue its operations.
• The company will continue the usability study for the PressureSafe device at Methodist Healthcare.

Key Dates

Keywords

medical devices, infrared spectroscopy, artificial intelligence, pressure injuries, diabetic foot ulcers, FDA, clinical trials, financial results, research and development, healthcare